Hogan Lovells has advised HLS Therapeutics Inc. on the deal. HLS Therapeutics Inc. (TSX: HLS) sold its royalty interest and milestone payment obligations in the global...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Hogan Lovells guided Optinose, Inc. on the deal. Optinose, Inc. (NASDAQ:OPTN) has completed a registered direct offering of approximately US$55 million of its common stock and...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
You must be a Standard 1 Year member to access this content.
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised EyePoint Pharmaceuticals on its offering. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) closed its US$230 million follow-on public offering of 13,529,411 shares of common stock...
You must be a Standard 1 Year member to access this content.
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal. Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Among other uses, this...
You must be a Standard 1 Year member to access this content.
